C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

(2011) B. I. Rini et al.   JNCI-Journal of the National Cancer Institute

Tumor Size Is a Potential Predictor of Response to Tyrosine Kinase Inhibitors in Renal Cell Cancer

(2011) Takeshi Yuasa et al.   UROLOGY

Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma

(2010) Y. Tomita et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients

(2009) Sei Naito et al.   EUROPEAN UROLOGY

A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety

(2009) H. Uemura et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma

(2008) Kazutaka Saito et al.   EUROPEAN UROLOGY